Pharmaceutical reimbursement frameworks determine whether and at what price new therapies reach patients through public and private payers, critically shaping access and commercial outcomes. Health technology assessment bodies employ various methodologies, cost-effectiveness analysis, budget impact modelling, and multi-criteria decision analysis, to inform coverage decisions. Innovative reimbursement mechanisms including outcome-linked payments and indication-specific pricing are increasingly applied to high-cost therapies.
